Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: The invention relates to a dosing regimen for administering a liquid pharmaceutical composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and administering a second dose of amantadine hydrochloride. The step of administering a first dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The step of administering a second dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The second dose is administered after at least about four to at least about six hours after the completion of administration of the first dose.

Abstract: Compositions comprising cannabidiol and one or more compounds which are inhibitors of CYP2C19 and CYP3A4 enzymes are disclosed. Methods of treating pain, epilepsy, sleep deprivation, vomiting, nausea, psychosis, anxiety, depression, movement disorders, and other neuropsychiatric or neurogenic diseases using such compositions are also provided. Compositions comprising cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof; and at least one therapeutic agent which is metabolized by CYP2C19, and optionally CYP3A4, are provided. Methods for inhibiting CYP2C19, and optionally CYP3A4, in a patient in need thereof are also provided, comprising administering to the patient an amount of cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof, effective for inhibiting CYP2C19, and optionally CYP3A4, in the patient.

Abstract: Provided herein are compositions, delivery devices, and methods relating to the delivery of tetrabenazine and/or deuterated tetrabenazine, for example, continuous or substantially continuous delivery such as transdermal delivery, for the treatment of a hyperkinetic movement disorder. Also provided are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, pharmaceutical compositions comprising tetrabenazine and/or a deuterated tetrabenazine, methods of preparing the same, and methods of using the same for example, for the treatment of a hyperkinetic movement disorder.

Abstract: Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.

Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilization of stem cells.

Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells.

Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I), wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilization of stem cells.

Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I), wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells.

Abstract: A method of treating an individual having a disease or for diagnostic purposes requiring administration of a corticosteroid, which involves applying to a portion of intact derma on the individual a transdermal patch having a backing layer and a matrix adhesive layer. The matrix adhesive layer includes a skin-compatible pressure-sensitive adhesive, a corticosteroid, and at least one permeation enhancer. The matrix adhesive layer, when applied to the skin of the individual, transdermally and continuously delivers the corticosteroid to the mammal for systemic treatment of the disease or for the diagnostic purpose.

Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.

Abstract: The methods of the invention treat vaginal fungal and yeast infections. More particularly, according to the methods of the invention, solid dosage forms may be administered to patients to treat vaginal fungal and yeast infections subsequent to awakening at any time during the day more than thirty minutes prior to retiring to sleep for the night.

Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive, wherein a plasma concentration of the 5-HT3 receptor antagonist in a therapeutically effective range is provided for period of time from an onset time to 12 hours or more after the composition is removed.

Abstract: This invention relates to methods, compositions and treatment regimens for applying cooling active ingredients to the perineum of a woman to treat the symptoms of a vaginal or vulvar infection or vulvar pain in order to speed the woman's relief from pain and/or itch.

Abstract: The methods of the invention treat vaginal fungal and yeast infections. More particularly, according to the methods of the invention, solid dosage forms may be administered to patients to treat vaginal fungal and yeast infections subsequent to awakening at any time during the day more than thirty minutes prior to retiring to sleep for the night.

Abstract: This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent as well as gel and jelly compositions related thereto. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.

Abstract: This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyols and preferably an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.

Abstract: A stable personal lubricant composition containing at least one water soluble polyhydric alcohol, a water soluble polymer derived from cellulose, tocopherol or a tocopherol derivative, an emulsifier and water.